APR346 is being investigated in a phase I study in combination with AZA/VEN for newly diagnosed TP53 mutated myeloid malignancies (NCT04214860) and being assessed in combination with azacitidine following allo-SCT as maintenance therapy in TP53 mutated AML/MDS (NCT03931291). This evidence concerns the gene TP53 and acute myeloid leukemia.